Trial Profile
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jun 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 15 Nov 2017 Status changed from active, no longer recruiting to completed.
- 11 Oct 2017 Planned primary completion date changed from 23 Oct 2017 to 3 Nov 2017.
- 31 Jan 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.